Correvio slumps after FDA staffers say benefits of heart drug do not outweigh risks

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 6, 2019 at 9:52 PM.

  1. #1 cafead, Dec 6, 2019 at 9:52 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp’s heart drug said on Friday they did not believe the benefits of the therapy outweighed its risks, sending the company’s shares down nearly 38%.

    article source
     
    Quote

Reply to Thread